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Summary
Plasma exchange is used increasingly as an individual therapeutic decision for
treating of severe, steroid-resistant relapses of multiple sclerosis (MS).
However, given that its mechanism of action in this CD4+ T cell-mediated
autoimmune disease remains unknown, it is not yet considered as a routine
therapy for this prevalent neuroimmune disorder. In this regard, we hypo-
thesized that plasma exchange, by depleting the body of inflammatory media-
tors that acts as providers of co-stimulatory signals for the adaptive immune
system, provides the immune system with an exceptional break for de-novo
recognition of autoantigens in a tolerogenic manner. This may lead to an
increase in the frequency and function of myelin-specific regulatory T cells.
For evaluating this we suggest some in vitro and in vivo studies to analyse the
effects of varied dilutions of normal and MS plasmas on the induction of
regulatory T cells or on the function of isolated and purified regulatory
T cells. Clarifying the effects of therapeutic plasma exchange on regulatory
T cells as the major controllers of autoimmune responses may provide us with
strong evidence to use this procedure as a disease-modifying treatment
in remission phase for reducing the rate and severity of future attacks, in
addition to more trustworthy therapy in severe relapses of MS.
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Administration of high doses of intravenous corticosteroids
(CS), such as methylprednisolone, is the regular therapy for
acute relapses of multiple sclerosis (MS). Although this
routine treatment is generally effective for relieving symp-
toms of an attack in the short term, it does not appear to have
a momentous impact on long-term recovery from disease.
Additionally, in some patients suffering from severe steroid-
resistant relapses, the clinical response to CS therapy may be
inadequate. Such patients could obtain clinical benefit from
following plasma exchange (PE) therapy. PE is considered
increasingly as an individual treatment in patients with
severe relapses not responding appropriately to CS.However,
because of the lack of proper studies and the unknown
mechanism of action, PE is not carried out as an enduring
disease-modifying strategy in MS patients [1], while it is an
established therapy for the treatment of many other neu-
roimmune disorders, such as myasthenia gravis, Lambert–
Eaton syndrome, Guillain–Barré syndrome and chronic
demyelinating polyneuropathy [2,3]. The purpose of the PE
procedure is to deplete the blood of various immunological
factors, such as antibodies, complement components,
chemokines, cytokines and almost all known and unknown
inflammatory factors with which their over-production in
the patient’s body may be associated with the initiation or
progression of the disease process [1]. Clearly, this mecha-
nism cannot directly cause all the improving effects of
plasma exchange in a cell-mediated autoimmune disease
such as MS, in view of the fact that these soluble factors are
made by cells and the original producer cells will still be in
the body after plasmapheresis is completed. In this regard,
some previous studies have shown that plasmapheresis, in
addition to depleting the antibodies and other soluble
factors from the blood, may affect the frequency and pheno-
type of different immune cell populations [4–10], and also
the function of these cells and production of some cytokines
and other soluble factors [11–16]. Regulatory T cells are
known as the most important players in maintaining
immune system homeostasis and tolerance to self-antigens
[17,18], and are also accepted as the main controllers of
MS [19–21]. One study has shown that the plasmapheresis
treatment of systemic lupus erythematosus (SLE) patients
induced a significant increase in the number of peripheral
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CD4+CD25(high)forkhead box protein 2 (FoxP3+) regulatory
T cells in parallel to the decrease in disease activity [22].
According to these studies, it seems reasonable to suppose
that onemechanism by which plasmapheresis exerts its effect
on CD4+ T cell-mediated autoimmune diseases such as MS
may be through exertion of some effects on the frequency,
ratio and function of regulatory T cells.
The hypothesis
By depleting the body of inflammatory factors, plasmapher-
esis may give the immune system an opportunity to re-adjust
itself. Thismay be possible in part via induction of regulatory
T cells through reducing the inflammatory cytokines found in
the patients’ plasma.According to the established‘two-signal’
theory in basic immunology, it has long been accepted that
immune activation of T cells is irrefutably dependent upon
receiving co-stimulatory signals as the second signal in addi-
tion to specific antigen recognition by the T cell receptor
complex as theprimary stimulatory signal [23].TheB7/CD28
ligand/receptor system is one of the most important
co-stimulatory pathways. Any disruption occurring in this
signalling pathway results in suppression of the immune
responses by induction of functional unresponsiveness or
anergy in stimulated T lymphocytes, and in some cases brings
about antigen-specific tolerance [24]. Soluble inflammatory
factors and cytokines of the innate immune system are
the most important regulators of the expression of
co-stimulatorymolecules, such as B7 familymembers, on the
surface of antigen-presenting cells (APCs) [24–26]. Thus, in
the presence of inflammation, antigen recognition by specific
T cells is often associated with immune activation,whereas in
the absence of inflammatory factors the same antigen recog-
nition can cause the inductionof tolerance andunresponsive-
ness in these antigen-specific T cells and confer upon them
the phenotype and function of regulatory T cells. Because
plasma exchange washes the body of inflammatory agents, or
at least dilutes them in the blood and therefore in the whole
body, it may provide naive autoreactive T lymphocytes with
the opportunity of recognizing related self-antigens without
adequate co-stimulatory signals in a tolerogenic de-novo
manner. This may cause an increase in the induction of
inducible subpopulations of myelin-specific regulatory T
cells and also some improvement in the function of naturally
occurring regulatory T cells and pre-existing inducible regu-
latory T cells because of the changes in their cytokine milieu.
Evaluating the hypothesis
For investigating these probable effects, we suggest some in
vitro and in vivo studies, as follows:
1. In vitro studies to examine the effects of varied dilutions
of plasma or serum on the phenotype and inhibitory
functions of regulatory T cells;
2. To examine the effects of MS patients’ plasma or serum
on the phenotype and regulatory function of these cells in
comparison with plasma or serum of healthy individuals;
and
3. In vivo studies comparing the relative frequency and
inhibitory function of these cells before and after plasma
exchange therapy course in animal models or in MS
patients.
Implications of the hypothesis
If sufficient scientific evidence is provided to confirm posi-
tive effects of plasmapheresis on the frequency and func-
tion of regulatory T cells, this treatment will have the
potential for reducing the rate and severity of future
relapses in MS patients, in addition to relieving the symp-
toms of a present attack. Also, if this hypothesis is proven,
continuing efforts can be proposed for specified filtering of
the blood and depleting the body of defined inflammatory
factors that contrast with the induction or function of these
cells, instead of replacing the whole plasma, to perform a
more effective and safe treatment for MS and similar
autoimmune disorders.
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